Evidence map›Paper›PMID 19667175›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2009

Genetic evidence for the role of Erk activation in a lymphoproliferative disease of mice.

Michihiko Miyaji, Robert L Kortum, Rishi Surana, Wenmei Li, Kevin D Woolard, R Mark Simpson, Lawrence E Samelson, Connie L Sommers

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The LAT story: a tale of cooperativity, coordination, and choreography.Cold Spring Harbor perspectives in biology · 2010
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Michihiko MiyajiLaboratory of Cellular and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Robert L Kortum
Rishi Surana
Wenmei Li
Kevin D Woolard
R Mark Simpson
Lawrence E Samelson
Connie L Sommers
National Institutes of Health · USNational Cancer Institute · US

Funding

Biochemical Basis of T Cell ActivationZIABC010304 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SAMELSON, LAWRENCE · 2009 to 2025
$36.3M
Molecular Pathology Research for Cancer Diagnostics and BiomarkersZICBC010953 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SIMPSON, ROBERT · 2009 to 2025
$22.9M
BIOCHEMICAL BASIS OF T CELL ACTIVATIONZ01BC010304 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SAMELSON, LAWRENCE E · 1999 to 2008
$2.6M
Intramural NIH HHS
6 · The paper itself

Abstract

Germline mutation of the linker for activation of T cells (LAT) gene at the phospholipase C-gamma1 (PLC-gamma1)-binding site leads to a fatal lymphoproliferative disease in mice. The hyperactivated T cells that develop in these mice have defective T-cell antigen receptor (TCR)-induced calcium flux but enhanced mitogen-activated protein kinase (MAPK) activation. We used genetic analysis to investigate genes whose products might suppress MAPK activation and lymphoproliferative disease in LAT mutant mice. B-lymphocyte adaptor molecule of 32 kDa (Bam32) is a known mediator of MAPK activation in B cells. We recently reported that in CD4(+) T cells, Bam32 deficiency decreased MAPK activation and specifically extracellular-signal-regulated kinase (Erk) signaling, following TCR stimulation. By crossing the Bam32 null mutation onto the LAT knock-in background, we found that the Bam32 null mutation delayed the onset and decreased the severity of lymphoproliferative disease in LAT knock-in mice. The pulmonary lymphocyte infiltration seen in LAT knock-in mice was also markedly decreased in double-mutant mice. Additionally, Erk activation was diminished in LAT knock-in Bam32 knockout CD4(+) T cells. To more accurately determine the role of Erk in this delay of lymphoproliferative disease, we also bred a transgenic, hypersensitive Erk allele (the Erk2 sevenmaker mutant) onto the LAT knock-in Bam32 knockout double-mutant background. These triple transgenic mice demonstrated a role for Erk activation in lymphoproliferative disease caused by the LAT knock-in mutation.

Indexed as

MutationAdaptor Proteins, Signal TransducingAnimalsApoptosisCalciumCD4-CD8 RatioCell ProliferationEnzyme ActivationEnzyme-Linked Immunosorbent AssayExtracellular Signal-Regulated MAP KinasesFlow CytometryInterleukin-4LipoproteinsLymphocytesLymphoproliferative DisordersMembrane ProteinsAdaptor Proteins, Signal TransducingCalciumDapp1 protein, mouseExtracellular Signal-Regulated MAP KinasesInterleukin-4Lat protein, mouseLipoproteinsMembrane ProteinsPhosphoproteinsReceptors, Antigen, T-Cell

Identifiers

PMID19667175
PMCPMC2732887
OpenAlexW2000733605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.